Researchers have made significant progress in the fight against pancreatic cancer by developing an affordable blood test designed to detect the disease in its early stages. This advancement comes from a team at Oregon Health & Science University (OHSU), which has reported that the new test can identify crucial changes in a specific enzyme involved in protein breakdown known as protease. Their findings were published in a medical journal focused on translational medicine.
Named PAC-MANN, which stands for “protease activity-based assay using a magnetic nanosensor,” the test aims to catch pancreatic cancer early, a particularly challenging task as the disease often remains silent until it’s too late for effective treatment. Dr. Jared Fischer from OHSU emphasized that earlier detection means more treatment options and a greater chance of survival for patients.
Pancreatic cancer is known for its high mortality rate, typically presenting few symptoms until it becomes advanced. According to the Pancreatic Cancer Action Network, the five-year survival rate is grim, with only 44% for early-stage cases confined to the pancreas and just 13% across all stages.
The PAC-MANN test boasts impressive results, accurately distinguishing between blood samples of those with pancreatic cancer and those without in 98% of cases. When combined with another existing test, it can diagnose early-stage pancreatic cancer with an accuracy of 85%.
Notably, the test requires only a tiny blood sample and can be processed in under an hour, significantly reducing costs. Dr. Jose L. Montoya Mira, the lead engineer behind the research, highlighted that the test uses merely 8 microliters of blood and takes less than a penny to conduct per sample, making it a viable option for rural and underserved communities.
Furthermore, this test could be particularly beneficial for individuals at high risk of developing pancreatic cancer, which is an area often overlooked by current diagnostic methods. The researchers hope that innovations like PAC-MANN will contribute to a future where early detection and treatment can lead to better outcomes for patients battling cancer.
